Home » Stocks » AGEN

Agenus Inc. (AGEN)

Stock Price: $3.66 USD -0.30 (-7.58%)
Updated Mar 2, 2021 4:00 PM EST - Market closed
Market Cap 692.14M
Revenue (ttm) 91.41M
Net Income (ttm) -173.57M
Shares Out 182.67M
EPS (ttm) -1.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 2
Last Price $3.66
Previous Close $3.96
Change ($) -0.30
Change (%) -7.58%
Day's Open 3.98
Day's Range 3.62 - 4.03
Day's Volume 5,364,589
52-Week Range 1.82 - 5.95

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 3 weeks ago

LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and v...

GlobeNewsWire - 3 weeks ago

LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and v...

GlobeNewsWire - 3 weeks ago

LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and v...

Benzinga - 3 weeks ago

Agenus Inc (NASDAQ: AGEN) has announced positive preliminary results from its Phase 1 trial evaluating its iNKT cell therapy in patients with moderate to severe symptoms of COVID-19 through it...

GlobeNewsWire - 3 weeks ago

LEXINGTON, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and v...

GlobeNewsWire - 1 month ago

LEXINGTON, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and v...

GlobeNewsWire - 2 months ago

Agenus to fulfill FDA feedback for six-month follow-up on late responders Agenus to fulfill FDA feedback for six-month follow-up on late responders

GlobeNewsWire - 3 months ago

LEXINGTON, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and v...

GlobeNewsWire - 3 months ago

LEXINGTON, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and v...

Seeking Alpha - 3 months ago

Agenus is nearing multiple upward inflection points. iNKT therapy trial started, showing immunotherapy leadership.

GlobeNewsWire - 3 months ago

LEXINGTON, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) --  Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and ...

GlobeNewsWire - 3 months ago

LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and v...

GlobeNewsWire - 3 months ago

LEXINGTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and v...

GlobeNewsWire - 3 months ago

LEXINGTON, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) --  Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and ...

The Motley Fool - 4 months ago

An off-the-shelf cell therapy for COVID-19 is sending the biotech's shares higher today.

GlobeNewsWire - 4 months ago

LEXINGTON, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers ...

Seeking Alpha - 4 months ago

Agenus Inc. (AGEN) CEO Garo Armen on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 4 months ago

Agenus (AGEN) delivered earnings and revenue surprises of -7.69% and 5.95%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 4 months ago

LEXINGTON, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and v...

Zacks Investment Research - 4 months ago

Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 4 months ago

Conference Call and Webcast on Thursday, October 29, 2020 from 8:30 – 9:30 am Conference Call and Webcast on Thursday, October 29, 2020 from 8:30 – 9:30 am

GlobeNewsWire - 4 months ago

LEXINGTON, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vac...

GlobeNewsWire - 4 months ago

LEXINGTON, Mass., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vac...

Seeking Alpha - 5 months ago

Agenus Vs. Seattle Genetics Cervical Cancer Clinical Trial Results

Other stocks mentioned: SGEN
Seeking Alpha - 5 months ago

MK-4830 Phase 1 early results are positive.

Zacks Investment Research - 5 months ago

Agenus (AGEN) initiates the rolling submission of its BLA to the FDA for balstilimab alone for the treatment of recurrent/metastatic cervical cancer.

GlobeNewsWire - 5 months ago

LEXINGTON, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and ...

GlobeNewsWire - 5 months ago

LEXINGTON, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and ...

GlobeNewsWire - 5 months ago

LEXINGTON, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and ...

GlobeNewsWire - 5 months ago

LEXINGTON, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and ...

The Motley Fool - 5 months ago

Investor optimism is increasing ahead of an oral presentation at ESMO 2020.

PRNewsWire - 6 months ago

LEXINGTON, Mass., Aug. 26, 2020 /PRNewswire/ -- Agenus Inc.

Seeking Alpha - 6 months ago

Agenus: Serial Underperformer's Deep I-O Pipeline Approaching Key Inflection Points

Zacks Investment Research - 6 months ago

Agenus (AGEN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Seeking Alpha - 6 months ago

Agenus Approaches Stock-Propelling Events

Seeking Alpha - 6 months ago

Agenus Inc. (AGEN) CEO Garo Armen on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Agenus (AGEN) delivered earnings and revenue surprises of -3.70% and 188.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

PRNewsWire - 6 months ago

LEXINGTON, Mass., Aug. 6, 2020 /PRNewswire/ -- Agenus Inc.

Zacks Investment Research - 6 months ago

Agenus (AGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

PRNewsWire - 7 months ago

LEXINGTON, Mass., July 29, 2020 /PRNewswire/ -- Agenus Inc.

PRNewsWire - 7 months ago

LEXINGTON, Mass., July 28, 2020 /PRNewswire/ -- Agenus Inc.

PRNewsWire - 7 months ago

LEXINGTON, Mass., July 21, 2020 /PRNewswire/ -- Agenus Inc.

Zacks Investment Research - 7 months ago

Does Agenus (AGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Seeking Alpha - 7 months ago

With Multiple Late Stage Cancer Therapies, Agenus Inc. Offers The Best Risk/Reward Profile In Biotechnology

Zacks Investment Research - 7 months ago

Agenus Inc. (AGEN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Zacks Investment Research - 8 months ago

Does Agenus (AGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Forbes - 8 months ago

If you’re looking to hedge against a coming pullback in the markets, we've used our deep learning algorithms and AI to identify the Top Shorts today.

Other stocks mentioned: ATOM, AXLA, EYPT, MGEN
Zacks Investment Research - 8 months ago

Is (AGEN) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor in Agenus.

Forbes - 8 months ago

If you’re looking for some hedges for your portfolio or are looking to shift against the market, our deep learning algorithms and AI technology have several Top Shorts for you today.

Other stocks mentioned: AMRS, INSE, OPGN, RTIX

About AGEN

Agenus, a clinical-stage immuno-oncology company, discovers, manufactures, and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes; and QS-21... [Read more...]

Industry
Biotechnology
IPO Date
Feb 4, 2000
CEO
Garo Armen
Employees
328
Stock Exchange
NASDAQ
Ticker Symbol
AGEN
Full Company Profile

Financial Performance

In 2019, Agenus's revenue was $150.05 million, an increase of 307.92% compared to the previous year's $36.78 million. Losses were -$107.66 million, -32.58% less than in 2018.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Agenus stock is "Strong Buy." The 12-month stock price forecast is 8.00, which is an increase of 118.58% from the latest price.

Price Target
$8.00
(118.58% upside)
Analyst Consensus: Strong Buy